Loading
A phase 3 trial of Ixabepilone, Doxorubicin and Paclitaxel / nab-paclitaxel in Endometrial cancer, run by R-Pharm, recorded as terminated on the registry.
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer is a phase 3 interventional study registered as NCT00883116 by R-Pharm, with 551 participants recorded, started 2009-08 and due to reach its primary completion in 2012-06. Interventions recorded: Ixabepilone, Doxorubicin, Paclitaxel. Conditions recorded: Endometrial Cancer.
Linked to the drug Ixabepilone because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
551 enrolled.
95% CI 8.5 to 12.7; Figures from the ClinicalTrials.gov results section (first posted 2014-03-14), not from a publication · 95% CI 10.7 to 15.4
Source95% CI 2.8 to 4.2; Figures from the ClinicalTrials.gov results section (first posted 2014-03-14), not from a publication · 95% CI 2.7 to 4.3
Source95% CI 10.8 to 20.6; Figures from the ClinicalTrials.gov results section (first posted 2014-03-14), not from a publication · 95% CI 11.2 to 21.1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Ixabepilone, 40 mg/m^2, Intravenously (IV) | 248 | 10.9 months | 1.3 (1 to 1.7) | 0.0397 | link |
| Control With Chemotherapy (Paclitaxel or Doxorubicin) | 248 | 12.3 months | ||||
| Progression-free Survival | Ixabepilone, 40 mg/m^2, Intravenously (IV) | 223 | 3.4 months | 1 (0.8 to 1.3) | 0.8011 | link |
| Control With Chemotherapy (Paclitaxel or Doxorubicin) | 223 | 4 months | ||||
| Best Overall Response Rate | Ixabepilone, 40 mg/m^2, Intravenously (IV) | 223 | 15.2% | - | - | link |
| Control With Chemotherapy (Paclitaxel or Doxorubicin) | 223 | 15.7% |
Shares Ixabepilone and the tag pipeline.
Shares R-Pharm and the tag pipeline.
Shares Doxorubicin, Endometrial cancer and the tag pipeline.
Shares Ixabepilone and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.
Shares Doxorubicin, Endometrial cancer and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.